- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Philips debuts high-end, low-cost MR scanners
Philips Healthcare unveiled two MR scanners on the RSNA 2008 exhibit floor: one at 3T, the other at 1.5T. Both emphasize productivity and clinical value, albeit by different means.
Philips Healthcare unveiled two MR scanners on the RSNA 2008 exhibit floor: one at 3T, the other at 1.5T. Both emphasize productivity and clinical value, albeit by different means.
The Achieva 3.0T TX expands the range of 3T applications possible with routine scanning through higher speed and better image quality using a novel technology dubbed MultiTransmit RF management. This technology automatically adjusts the RF signal to the specific body habitus and anatomy of the patient being scanned. The results, according to Philips, are higher acquisition speed, as well as better image quality and consistency. Together they offer new clinical possibilities for scanning the breast, liver, pelvis, and spine at 3T, according to the company.
Philips extended its current 1.5T platform with the Achieva SE, a scanner designed for budget-constrained customers. The scanner combines high-performance imaging and low capital cost through a sub-$1 million price tag, lower operating costs, and compact siting. The same basic platform drives both the Achieva SE and the high-end Achieva 1.5T A-Series, but the new product is repackaged without the more advanced clinical capabilities of the A-Series. Power-saving features reduce energy consumption -- and energy costs -- by up to 50%, according to Philips.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
